India’s pharmaceutical market continues to expand, and with the growth comes greater responsibility for drug safety oversight. The Central Drugs Standard Control Organization (CDSCO) plays a central role in shaping the country’s pharmacovigilance framework.
Key Insight: Starting in 2026, CDSCO and the Drugs Control Authority (DCA) of Telangana have been enforcing stricter pharmacovigilance rules, including digital reporting, enhanced quality monitoring, and strict action against non-compliance. Owing to the rise in Not of Standard Quality (NSQ) drug reports, Telangana has also asked all medical shops to display QR codes and toll-free numbers for reporting adverse drug reactions to PvPI.
For pharmaceutical companies, importers, and marketing authorization holders, and pharmacy stores, understanding these expectations is essential for maintaining compliance and protecting patient safety.
As medicines move from development to real-world use, there is a high probability of new safety information emerging. This is why CDSCO PV regulations in India place strong emphasis on reporting, monitoring, and ongoing review. A well-functioning pharmacovigilance system depends on cooperation between regulators, industry, healthcare professionals, and public health programs.
CDSCO Reporting Requirements
One of the most important parts of the Pharmacovigilance framework is reporting the PV issues to local health authorities. Companies are expected to report adverse events accurately and within the required timelines. CDSCO adverse event reporting helps identify safety signals early, allowing regulators and manufacturers to take corrective action when needed.
These expectations are reinforced through CDSCO safety reporting requirements, which cover not only individual case safety reports but also broader safety observations that may affect product use. For companies operating in India, strong internal reporting processes are critical for meeting regulatory obligations and avoiding compliance gaps.
Key Insight: To ensure that the safety-related documentation is digitally accessible, CDSCO has  recently transitioned to mandatory online submissions via the Online National Drugs Licensing System (ONDLS) for product licenses.
Post-Marketing Surveillance in India
A medicine’s safety profile does not end at approval. Post-marketing surveillance is a key part of the lifecycle approach to safety monitoring. Once a product enters the market, it must continue to be evaluated in routine clinical use. This allows safety teams to detect trends, assess the severity of events, and determine whether updates are needed in labeling, risk communication, or usage guidance.
Hence, drug safety monitoring in India becomes an ongoing responsibility rather than a one-time regulatory milestone. Companies that invest in active surveillance and robust case processing are better positioned to respond quickly when concerns arise.
Key Insight: Telangana has taken a stricter approach to drug quality checks in early 2026. It flagged several drugs as Not of Standard Quality. This means companies must be ready to act quickly with product recalls and root-cause analysis.
Role of PvPI and Regulatory Compliance
India’s national safety ecosystem is also supported by PVPI guidelines, which strengthen the country’s adverse event reporting network. These guidelines help create a more coordinated approach to collecting and reviewing safety data across hospitals, healthcare professionals, and industry partners.
For organizations in India, aligning internal processes with the CDSCO regulatory framework is essential for pharmacovigilance compliance. This includes timely reporting, quality case management, signal evaluation, documentation, and escalation when needed. A reliable compliance system not only supports regulatory readiness but also reinforces trust in the product and the organization behind its development.
Building a Strong PV Approach
A strong pharmacovigilance program is no longer optional. It is a core regulatory and quality function that supports the development of safer medicines and stronger public health outcomes. By building a compliant pharmacovigilance system, companies can respond effectively to evolving expectations and maintain alignment with India’s drug safety regulations as mandated by the CDSCO.
For pharmaceutical companies, the message is clear: pharmacovigilance is not just a regulatory requirement. It is a long-term commitment to patient safety, product integrity, and responsible market presence.
If manufacturers fail to meet safety standards and PV requirements, the DCA may issue immediate stop-production orders, which could damage the organization’s brand image.
Need support with pharmacovigilance compliance in India? Vigilare Biopharma helps pharmaceutical companies navigate CDSCO pharmacovigilance guidelines, reporting expectations, and post-marketing safety requirements with confidence.